Today, Heidi Overton, chosen by President Trump to run the Food and Drug Administration, will face senators at 10:30 a.m. at a Senate committee hearing. Confirmation would make her the youngest person ever to hold the post, at 37 years old.
Dr. Overton served as a preventive medicine physician during both terms of the Trump administration. Her managerial experience has been questioned by lawmakers and industry leaders alike. She has also faced criticism for adopting policies championed by Health Secretary Robert F. Kennedy Jr.
Sen. Bill Cassidy (R-La.), chairman of the Senate Committee on Health, Education, Labor and Pensions, has criticized her role in shaping the administration’s efforts to roll back the childhood vaccine schedule.
The Hearing Today
The FDA has weathered a turbulent 18 months of politicized decisions and staff departures. The 2025 reductions-in-force cut the agency’s numbers by nearly 20 percent.
Should Overton’s confirmation go through, it would signal a generational change at the FDA’s highest levels. She would be the youngest person ever to serve in that role, taking office at 37.
The hearing gives senators a chance to test her qualifications. The stakes are high. Overton will need to answer questions about her experience managing large organizations, her position on vaccine policy, and how she handles conflicts between political pressure and scientific evidence. Her replies could set the course for how the FDA functions for years down the road.
Overton’s Record
Dr. Overton is a preventive medicine doctor who has served in both of President Trump’s terms in office. She has worked under two administrations, and her record includes time spent serving as a preventive medicine physician.
Some critics argue she follows policies championed by Health Secretary Robert F. Kennedy Jr., which has drawn questions about her ability to act independently and free from political pressure.
Sen. Bill Cassidy (R-La.), chairman of the Senate Committee on Health, Education, Labor and Pensions, has criticized her role in shaping the administration’s push to roll back the childhood vaccine schedule. The criticism comes from the same senator who will be leading the questioning today.
The Vaccine Criticism
Sen. Bill Cassidy (R-La.) has publicly criticized Overton’s past work on vaccines. His criticism puts him in direct conflict with the administration’s nominee.
Overton will face questioning today, and Cassidy, who serves as chairman of the Senate Committee on Health, Education, Labor and Pensions, will be among those doing the asking. The critique focuses on Overton’s part in reversing the childhood vaccine schedule.
The FDA’s Turbulent Year
The FDA has had a difficult 18 months. The agency has faced politicized decisions and staff departures.
The 2025 reductions-in-force cut the agency’s numbers by nearly 20 percent. The agency has also faced scrutiny over its decision-making.
The FDA has weathered a turbulent 18 months of politicized decisions and staff departures. The 2025 reductions-in-force cut the agency’s numbers by nearly 20 percent.
Key Questions
The session will draw close attention, with Overton’s replies potentially setting the course for how the FDA functions for years down the road.
Senators will likely ask about:
- Her experience managing large organizations
- How she handles conflicts between political pressure and scientific evidence
- Her position on vaccine policy
Today at 10:30 a.m., Overton faces a hearing that will determine whether she is ready for one of the most powerful jobs in American health care. The timing is a test of her preparedness.
The stakes are high.
What Comes Next
Lawmakers will judge whether Overton has what it takes to lead the FDA during her hearing. The agency needs a leader who can deliver right now, and the test will show if she measures up.
The agency has endured a difficult stretch. Overton now has an opportunity to rebuild trust. It is unknown if she will succeed.
Today’s hearing begins at 10:30 a.m., and everyone present will be watching Overton.
Where the paper stands
The paper backs the FDA confirmation process staying free of Washington’s usual habits and is against any new office gathering more power under the guise of protecting health, whatever its name. Dr. Overton’s confirmation hearing today tests whether the FDA stays an independent agency or becomes another office writing its own authority.
The FDA has already suffered 18 months of politicized decisions and staff departures. The 2025 reductions-in-force cut the agency’s numbers by nearly 20 percent. Now the administration wants to confirm a nominee whose record raises questions about her independence, and whose policy stances have drawn public criticism from Sen. Bill Cassidy, the very senator who will be leading the questioning today. The pattern of an agency losing staff while Washington hands it a new leader is exactly the kind of concentration of power the paper warns against.
Senators should ask Dr. Overton directly about her experience managing large organizations, her position on vaccine policy, and how she handles conflicts between political pressure and scientific evidence. The paper hopes the hearing exposes the administration’s nominee for what she is rather than confirms her into a job where she can gather more power.
See the a run of 25 images at STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.